The abstract is read at the publisher; the summary is JClub's.
PTM-modified cathelicidin LL37 and CXCL4 (PF4) act as bifunctional autoantigens in psoriasis, psoriatic arthritis, SLE, and SSc by simultaneously driving innate inflammation and adaptive autoimmunity.
- Why it matters: PTMs can create neo-epitopes that escape tolerance, but the field lacks a unified view of how specific modified self-antigens both activate innate sensors and expand autoreactive T and B cell responses.
- What they did: The review synthesizes evidence that LL37 and CXCL4 form complexes with self- and microbial DNA/RNA, engaging pDCs/mDCs through DNA/RNA sensors including TLR7-9 and cGAS/STING, and also promote B-cell differentiation into antibody-producing plasma cells.
- The result: These dual effects amplify Type I interferon and cytokine storms and likely impair regulation, supporting targeting PTM-modified LL37 and CXCL4 to dampen inflammatory cascades and restore tolerance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.